Monte Rosa Therapeutics Inc $GLUE

Recent News (5)

• Rapafusyn Pharmaceuticals to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire · 02 Sep 2026 BALTIMORE, Sept. 2, 2026 /PRNewswire/ -- Rapafusyn Pharmaceuticals, a leader in the discovery and development of non-degrading molecular glue therapeutics, today announced that Dr. Sean Hu, President …
• Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire · 01 Sep 2026 Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
• Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma GlobeNewswire · 24 Aug 2026 Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer
• Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer GlobeNewswire · 24 Aug 2026 Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
• Social care in England: how could we pay to fix a ‘broken system’? The Guardian · 27 Jul 2026 Many across the political spectrum agree the system needs fixing – but there is no consensus on how to fund change The prime minister, Andy Burnham, has said the adult social care system in England is…